Neovasc Hires Industry Veteran Vicki Bebeau as Vice President, Clinical Affairs
-Bebeau Brings Her Extensive Experience in Managing Cardiac Device Clinical
Programs to the Tiara™ and Neovasc Reducer™ New Product Programs-
-New Clinical Initiatives for Tiara and the Neovasc Reducer Targeted for 2014
TSX Venture Exchange: NVC
VANCOUVER, May 8, 2014 /CNW/ - Neovasc Inc. (TSXV: NVC) (the 'Company' or
'Neovasc') today announced that Vicki Bebeau has joined the company in the
role of Vice President, Clinical Affairs, a newly-created position. Ms. Bebeau
brings Neovasc more than 18 years of experience in clinical trial planning and
management at industry leaders St. Jude Medical, Boston Scientific and
"With the ongoing successes of our Tiara™ mitral valve and Neovasc
Reducer™ programs, Neovasc is preparing to undertake clinical trial
initiatives for both products," noted Alexei Marko, CEO of Neovasc. "We plan
to initiate multinational feasibility studies for Tiara in late 2014, and we
are targeting a 2015 start for the Reducer clinical program needed for an IDE
approval in the United States."
Mr. Marko added, "These high potential programs are central to our success and
we are delighted to have recruited Vicki Bebeau, a highly experienced industry
veteran, as our head of Clinical Affairs. Ms. Bebeau has held clinical
positions of increasing responsibility at medical device industry leaders St.
Jude Medical, Boston Scientific and Medtronic, where she successfully directed
multinational clinical studies in Canada, the United States, and Europe."
Neovasc is preparing to begin formal clinical feasibility studies for its
Tiara device for the transcatheter treatment of mitral valve disease later
this year. In addition, building on positive results recently reported from
the Reducer COSIRA trial, Neovasc has initiated design of a US-IDE study to
support an application for FDA approval of the Reducer. The study is expected
to begin next year.
"Neovasc has earned a strong reputation in the industry for their development
of novel cardiovascular devices addressing major unmet medical needs, and I
look forward to playing a key role in advancing the clinical programs that are
central to the clinical and commercial success of the Tiara and Reducer new
product programs," commented Ms. Bebeau.
Neovasc intends to continue the expansion of its clinical team and related
operations to support the Tiara and Reducer product programs.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and
markets products for the rapidly growing cardiovascular marketplace. Its
products include the Tiara™ technology in development for the transcatheter
treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of
refractory angina and a line of advanced biological tissue products that are
used as key components in third-party medical products including transcatheter
heart valves. For more information, visit www.neovasc.com
Statements contained herein that are not based on historical or current fact,
including without limitation statements containing the words "anticipates,"
"believes," "may," "continues," "estimates," "expects," "forecasts",
"targets", and "will" and words of similar import, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995. Such forward looking statements, including the forecasted
start date for the formal clinical feasibility studies of the Tiara and the
targeted FDA approval application for the Reducer, involve known and unknown
risks, uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements. Such factors include, among others, the following: general
economic and business conditions, both nationally and in the regions in which
the Company operates; history of losses and lack of and uncertainty of
revenues, ability to obtain required financing, receipt of regulatory approval
of product candidates, ability to properly integrate newly acquired
businesses, technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified personnel;
existing governmental regulations and changes in, or the failure to comply
with, governmental regulations; liability and other claims asserted against
the Company; and other factors referenced in the Company's filings with
securities regulators. Although the Company believes that expectations
conveyed by the forward-looking statements are reasonable based on the
information available to it on the date such statements were made, no
assurances can be given as to the future results, approvals or achievements.
Given these uncertainties, readers are cautioned not to place undue reliance
on such forward-looking statements. The Company does not assume the obligation
to update any forward-looking statements except as otherwise required by
SOURCE Neovasc Inc.
Corporate Contact: Chris Clark Neovasc Inc. 604 248-4138 email@example.com
U.S. Media & investor Contact: BLL Partners, LLC Barbara Lindheim 212 584-2276
To view this news release in HTML formatting, please use the following URL:
CO: Neovasc Inc.
ST: British Columbia
NI: MTC 2575 WNEWS
-0- May/08/2014 11:00 GMT
Press spacebar to pause and continue. Press esc to stop.